메뉴 건너뛰기




Volumn 5, Issue , 2015, Pages

Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM; PROTEIN BAX; PROTEIN BCL 2;

EID: 84949565155     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17766     Document Type: Article
Times cited : (18)

References (57)
  • 1
    • 79952232216 scopus 로고    scopus 로고
    • Global cancer statistics
    • Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69-90, doi: 10.3322/caac.20107 (2011).
    • (2011) CA: A Cancer Journal for Clinicians , vol.61 , pp. 69-90
    • Jemal, A.1
  • 2
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    • Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England journal of medicine 346, 92-98, doi: 10.1056/NEJMoa011954 (2002).
    • (2002) The New England Journal of Medicine , vol.346 , pp. 92-98
    • Schiller, J.H.1
  • 3
    • 84872503488 scopus 로고    scopus 로고
    • Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy
    • Lindner, A. U. et al. Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. Cancer research 73, 519-528, doi: 10.1158/0008-5472.CAN-12-2269 (2013).
    • (2013) Cancer Research , vol.73 , pp. 519-528
    • Lindner, A.U.1
  • 5
    • 0032575688 scopus 로고    scopus 로고
    • The Bcl-2 protein family: Arbiters of cell survival
    • Adams, J. M. & Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326 (1998).
    • (1998) Science , vol.281 , pp. 1322-1326
    • Adams, J.M.1    Cory, S.2
  • 6
    • 14044251695 scopus 로고    scopus 로고
    • Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution
    • Kroemer, G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell death and differentiation 4, 443-456, doi: 10.1038/sj.cdd.4400266 (1997).
    • (1997) Cell Death and Differentiation , vol.4 , pp. 443-456
    • Kroemer, G.1
  • 7
    • 0027166048 scopus 로고
    • Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
    • Oltvai, Z. N., Milliman, C. L. & Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619 (1993).
    • (1993) Cell , vol.74 , pp. 609-619
    • Oltvai, Z.N.1    Milliman, C.L.2    Korsmeyer, S.J.3
  • 8
    • 0030772022 scopus 로고    scopus 로고
    • Target to apoptosis: A hopeful weapon for prostate cancer
    • Tang, D. G. & Porter, A. T. Target to apoptosis: a hopeful weapon for prostate cancer. The Prostate 32, 284-293 (1997).
    • (1997) The Prostate , vol.32 , pp. 284-293
    • Tang, D.G.1    Porter, A.T.2
  • 9
    • 0034025130 scopus 로고    scopus 로고
    • Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas
    • Bukholm, I. K. & Nesland, J. M. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Archiv: an international journal of pathology 436, 224-228 (2000).
    • (2000) Virchows Archiv: An International Journal of Pathology , vol.436 , pp. 224-228
    • Bukholm, I.K.1    Nesland, J.M.2
  • 11
    • 34848892766 scopus 로고    scopus 로고
    • Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck
    • Chen, K. et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 28, 2008-2012, doi: 10.1093/carcin/bgm172 (2007).
    • (2007) Carcinogenesis , vol.28 , pp. 2008-2012
    • Chen, K.1
  • 12
    • 84876591115 scopus 로고    scopus 로고
    • Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population
    • Dorjgochoo, T. et al. Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population. PloS one 8, e60915, doi: 10.1371/journal.pone.0060915 (2013).
    • (2013) PLoS One , vol.8 , pp. e60915
    • Dorjgochoo, T.1
  • 13
    • 62049084351 scopus 로고    scopus 로고
    • Bcl2-938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy
    • Hirata, H. et al. Bcl2-938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. The Journal of urology 181, 1907-1912, doi: 10.1016/j.juro.2008.11.093 (2009).
    • (2009) The Journal of Urology , vol.181 , pp. 1907-1912
    • Hirata, H.1
  • 14
    • 79953236337 scopus 로고    scopus 로고
    • BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility
    • Zhang, N. et al. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC medical genetics 12, 48, doi: 10.1186/1471-2350-12-48 (2011).
    • (2011) BMC Medical Genetics , vol.12 , pp. 48
    • Zhang, N.1
  • 15
    • 84884760539 scopus 로고    scopus 로고
    • The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
    • Kunkele, A. et al. The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. BMC cancer 13, 452, doi: 10.1186/1471-2407-13-452 (2013).
    • (2013) BMC Cancer , vol.13 , pp. 452
    • Kunkele, A.1
  • 17
    • 33751541194 scopus 로고    scopus 로고
    • Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment
    • Rodriguez-Nieto, S. & Zhivotovsky, B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Current pharmaceutical design 12, 4411-4425 (2006).
    • (2006) Current Pharmaceutical Design , vol.12 , pp. 4411-4425
    • Rodriguez-Nieto, S.1    Zhivotovsky, B.2
  • 18
    • 0344393783 scopus 로고    scopus 로고
    • Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
    • Kaufmann, S. H. & Vaux, D. L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22, 7414-7430, doi: 10.1038/sj.onc.1206945 (2003).
    • (2003) Oncogene , vol.22 , pp. 7414-7430
    • Kaufmann, S.H.1    Vaux, D.L.2
  • 19
    • 84866753909 scopus 로고    scopus 로고
    • Independent transcriptional reprogramming and apoptosis induction by cisplatin
    • Galluzzi, L. et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell cycle 11, 3472-3480, doi: 10.4161/cc.21789 (2012).
    • (2012) Cell Cycle , vol.11 , pp. 3472-3480
    • Galluzzi, L.1
  • 20
    • 84873030541 scopus 로고    scopus 로고
    • Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy
    • Masago, K. et al. Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy. Oncology 84, 214-218, doi: 10.1159/000342854 (2013).
    • (2013) Oncology , vol.84 , pp. 214-218
    • Masago, K.1
  • 21
    • 79958008924 scopus 로고    scopus 로고
    • Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C> A) with better 2-year survival in patients with glioblastoma multiforme
    • El Hindy, N. et al. Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C> A) with better 2-year survival in patients with glioblastoma multiforme. Journal of neurosurgery 114, 1631-1639, doi: 10.3171/2010.12.JNS10478 (2011).
    • (2011) Journal of Neurosurgery , vol.114 , pp. 1631-1639
    • El Hindy, N.1
  • 22
    • 74849120847 scopus 로고    scopus 로고
    • BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients
    • Moon, J. H. et al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leukemia research 34, 166-172, doi: 10.1016/j.leukres.2009.05.009 (2010).
    • (2010) Leukemia Research , vol.34 , pp. 166-172
    • Moon, J.H.1
  • 23
    • 71049131735 scopus 로고    scopus 로고
    • BCL2-938C> A polymorphism and disease progression in chronic lymphocytic leukemia
    • Zenz, T. et al. BCL2-938C> A polymorphism and disease progression in chronic lymphocytic leukemia. Leukemia & lymphoma 50, 1837-1842, doi: 10.3109/10428190903207530 (2009).
    • (2009) Leukemia & Lymphoma , vol.50 , pp. 1837-1842
    • Zenz, T.1
  • 24
    • 67649831321 scopus 로고    scopus 로고
    • The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer
    • Hirata, H. et al. The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. The Journal of urology 182, 721-727, doi: 10.1016/j.juro.2009.03.081 (2009).
    • (2009) The Journal of Urology , vol.182 , pp. 721-727
    • Hirata, H.1
  • 25
    • 14944346868 scopus 로고    scopus 로고
    • Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated
    • Starczynski, J. et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23, 1514-1521, doi: 10.1200/JCO.2005.02.192 (2005).
    • (2005) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology , vol.23 , pp. 1514-1521
    • Starczynski, J.1
  • 26
    • 0037058662 scopus 로고    scopus 로고
    • Association of a novel single nucleotide polymorphism, G(-248)A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance
    • Saxena, A., Moshynska, O., Sankaran, K., Viswanathan, S. & Sheridan, D. P. Association of a novel single nucleotide polymorphism, G(-248)A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer letters 187, 199-205 (2002).
    • (2002) Cancer Letters , vol.187 , pp. 199-205
    • Saxena, A.1    Moshynska, O.2    Sankaran, K.3    Viswanathan, S.4    Sheridan, D.P.5
  • 27
    • 33846004731 scopus 로고    scopus 로고
    • Association of a novel regulatory polymorphism (-938C> A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia
    • Nuckel, H. et al. Association of a novel regulatory polymorphism (-938C> A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 109, 290-297, doi: 10.1182/blood-2006-03-007567 (2007).
    • (2007) Blood , vol.109 , pp. 290-297
    • Nuckel, H.1
  • 28
    • 34247261624 scopus 로고    scopus 로고
    • Bax gene G(-248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis
    • Ocana, M. G. et al. Bax gene G(-248)A promoter polymorphism is associated with increased lifespan of the neutrophils of patients with osteomyelitis. Genetics in medicine: official journal of the American College of Medical Genetics 9, 249-255, doi: 10.1097GIM.0b013e318039b23d (2007).
    • (2007) Genetics in Medicine: Official Journal of the American College of Medical Genetics , vol.9 , pp. 249-255
    • Ocana, M.G.1
  • 29
    • 35649024810 scopus 로고    scopus 로고
    • Understanding cisplatin resistance using cellular models
    • Stordal, B. & Davey, M. Understanding cisplatin resistance using cellular models. IUBMB life 59, 696-699, doi: 10.1080/15216540701636287 (2007).
    • (2007) IUBMB Life , vol.59 , pp. 696-699
    • Stordal, B.1    Davey, M.2
  • 30
    • 0022379447 scopus 로고
    • The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining
    • Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. & Croce, C. M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229, 1390-1393 (1985).
    • (1985) Science , vol.229 , pp. 1390-1393
    • Tsujimoto, Y.1    Gorham, J.2    Cossman, J.3    Jaffe, E.4    Croce, C.M.5
  • 31
    • 0023779204 scopus 로고
    • Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma
    • Seto, M. et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. The EMBO journal 7, 123-131 (1988).
    • (1988) The EMBO Journal , vol.7 , pp. 123-131
    • Seto, M.1
  • 32
    • 0027286622 scopus 로고
    • A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter
    • Young, R. L. & Korsmeyer, S. J. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Molecular and cellular biology 13, 3686-3697 (1993).
    • (1993) Molecular and Cellular Biology , vol.13 , pp. 3686-3697
    • Young, R.L.1    Korsmeyer, S.J.2
  • 33
    • 4544375763 scopus 로고    scopus 로고
    • Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2)
    • Park, B. L. et al. Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/lymphoma 2 (BCL2). Journal of human genetics 49, 449-454, doi: 10.1007/s10038-004-0173-0 (2004).
    • (2004) Journal of Human Genetics , vol.49 , pp. 449-454
    • Park, B.L.1
  • 34
    • 80052961223 scopus 로고    scopus 로고
    • Regulatory BCL2 promoter polymorphism (-938C> A) is associated with adverse outcome in patients with prostate carcinoma
    • Bachmann, H. S. et al. Regulatory BCL2 promoter polymorphism (-938C> A) is associated with adverse outcome in patients with prostate carcinoma. International journal of cancer. Journal international du cancer 129, 2390-2399, doi: 10.1002/ijc.25904 (2011).
    • (2011) International Journal of Cancer. Journal International du Cancer , vol.129 , pp. 2390-2399
    • Bachmann, H.S.1
  • 35
    • 66149168916 scopus 로고    scopus 로고
    • The regulatory BCL2 promoter polymorphism (-938C> A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma
    • Lehnerdt, G. F. et al. The regulatory BCL2 promoter polymorphism (-938C> A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 20, 1094-1099, doi: 10.1093/annonc/mdn763 (2009).
    • (2009) Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO , vol.20 , pp. 1094-1099
    • Lehnerdt, G.F.1
  • 36
    • 35348870611 scopus 로고    scopus 로고
    • The AA genotype of the regulatory BCL2 promoter polymorphism (938C> A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients
    • Bachmann, H. S. et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938C> A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 5790-5797, doi: 10.1158/1078-0432.CCR-06-2673 (2007).
    • (2007) Clinical Cancer Research: An Official Journal of the American Association for Cancer Research , vol.13 , pp. 5790-5797
    • Bachmann, H.S.1
  • 37
    • 76649120871 scopus 로고    scopus 로고
    • Association of the AA genotype of the BCL2 (-938C> A) promoter polymorphism with better survival in ovarian cancer
    • Heubner, M. et al. Association of the AA genotype of the BCL2 (-938C> A) promoter polymorphism with better survival in ovarian cancer. The International journal of biological markers 24, 223-229 (2009).
    • (2009) The International Journal of Biological Markers , vol.24 , pp. 223-229
    • Heubner, M.1
  • 39
    • 0037050735 scopus 로고    scopus 로고
    • Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines
    • Sartorius, U. A. & Krammer, P. H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. International journal of cancer. Journal international du cancer 97, 584-592 (2002).
    • (2002) International Journal of Cancer. Journal International du Cancer , vol.97 , pp. 584-592
    • Sartorius, U.A.1    Krammer, P.H.2
  • 40
    • 9144222021 scopus 로고    scopus 로고
    • Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer
    • Han, J. Y. et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Medical oncology 20, 355-362, doi: 10.1385/MO:20:4:355 (2003).
    • (2003) Medical Oncology , vol.20 , pp. 355-362
    • Han, J.Y.1
  • 41
    • 0032055269 scopus 로고    scopus 로고
    • Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma
    • Fontanini, G. et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. European journal of cancer 34, 718-723 (1998).
    • (1998) European Journal of Cancer , vol.34 , pp. 718-723
    • Fontanini, G.1
  • 42
    • 0041343301 scopus 로고    scopus 로고
    • Role of Bcl-2 as a prognostic factor for survival in lung cancer: A systematic review of the literature with metaanalysis
    • Martin, B. et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with metaanalysis. British journal of cancer 89, 55-64, doi: 10.1038/sj.bjc.6601095 (2003).
    • (2003) British Journal of Cancer , vol.89 , pp. 55-64
    • Martin, B.1
  • 43
    • 0029902618 scopus 로고    scopus 로고
    • The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas
    • Chou, D. et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer genetics and cytogenetics 88, 136-140 (1996).
    • (1996) Cancer Genetics and Cytogenetics , vol.88 , pp. 136-140
    • Chou, D.1
  • 44
    • 0036190881 scopus 로고    scopus 로고
    • Expression of Bcl-x, Bcl-2, Bax, and Bak in endarterectomy and atherectomy specimens
    • Saxena, A., McMeekin, J. D. & Thomson, D. J. Expression of Bcl-x, Bcl-2, Bax, and Bak in endarterectomy and atherectomy specimens. The Journal of pathology 196, 335-342, doi: 10.1002/path.1040 (2002).
    • (2002) The Journal of Pathology , vol.196 , pp. 335-342
    • Saxena, A.1    McMeekin, J.D.2    Thomson, D.J.3
  • 45
    • 0036392126 scopus 로고    scopus 로고
    • Bax-induction gene therapy of pancreatic cancer
    • Pirocanac, E. C. et al. Bax-induction gene therapy of pancreatic cancer. The Journal of surgical research 106, 346-351 (2002).
    • (2002) The Journal of Surgical Research , vol.106 , pp. 346-351
    • Pirocanac, E.C.1
  • 46
    • 15744399807 scopus 로고    scopus 로고
    • Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability
    • Miquel, C. et al. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. American journal of clinical pathology 123, 562-570, doi: 10.1309/JQ2X-3RV3-L8F9-TGYW (2005).
    • (2005) American Journal of Clinical Pathology , vol.123 , pp. 562-570
    • Miquel, C.1
  • 47
    • 0344348993 scopus 로고    scopus 로고
    • Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases
    • Sturm, I. et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17, 1364-1374 (1999).
    • (1999) Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology , vol.17 , pp. 1364-1374
    • Sturm, I.1
  • 48
    • 34547136180 scopus 로고    scopus 로고
    • Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy
    • Kang, S. Y. et al. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 4146-4153, doi: 10.1158/1078-0432.CCR-06-3063 (2007).
    • (2007) Clinical Cancer Research: An Official Journal of the American Association for Cancer Research , vol.13 , pp. 4146-4153
    • Kang, S.Y.1
  • 49
    • 33750584219 scopus 로고    scopus 로고
    • Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer
    • Porebska, I. et al. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In vivo 20, 599-604 (2006).
    • (2006) Vivo , vol.20 , pp. 599-604
    • Porebska, I.1
  • 50
    • 54949143174 scopus 로고    scopus 로고
    • Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with nonsquamous histology
    • Jeong, S. H. et al. Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with nonsquamous histology. Japanese journal of clinical oncology 38, 661-669, doi: 10.1093/jjco/hyn089 (2008).
    • (2008) Japanese Journal of Clinical Oncology , vol.38 , pp. 661-669
    • Jeong, S.H.1
  • 51
    • 84858187016 scopus 로고    scopus 로고
    • Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma
    • Anvari, K. et al. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma. Urology journal 9, 381-388 (2012).
    • (2012) Urology Journal , vol.9 , pp. 381-388
    • Anvari, K.1
  • 52
    • 84866749511 scopus 로고    scopus 로고
    • The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma
    • Yigit, S. et al. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma. Neoplasma 59, 475-485, doi: 10.4149/neo-2012-061 (2012).
    • (2012) Neoplasma , vol.59 , pp. 475-485
    • Yigit, S.1
  • 53
    • 84862584533 scopus 로고    scopus 로고
    • The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women
    • Lopes-Costa, P. V., dos Santos, A. R. & da Silva, B. B. The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women. Diagnostic cytopathology 40, 570-574, doi: 10.1002/dc.21580 (2012).
    • (2012) Diagnostic Cytopathology , vol.40 , pp. 570-574
    • Lopes-Costa, P.V.1    Dos Santos, A.R.2    Da Silva, B.B.3
  • 54
    • 84885817813 scopus 로고    scopus 로고
    • Lack of association between Bax promoter (-248G> A) single nucleotide polymorphism and susceptibility towards cancer: Evidence from a meta-analysis
    • Sahu, S. K. & Choudhuri, T. Lack of association between Bax promoter (-248G> A) single nucleotide polymorphism and susceptibility towards cancer: evidence from a meta-analysis. PloS one 8, e77534, doi: 10.1371/journal.pone.0077534 (2013).
    • (2013) PLoS One , vol.8 , pp. e77534
    • Sahu, S.K.1    Choudhuri, T.2
  • 55
    • 8944263468 scopus 로고    scopus 로고
    • Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
    • Perego, P. et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer research 56, 556-562 (1996).
    • (1996) Cancer Research , vol.56 , pp. 556-562
    • Perego, P.1
  • 56
    • 0029917541 scopus 로고    scopus 로고
    • Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2
    • Zha, H., Aime-Sempe, C., Sato, T. & Reed, J. C. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. The Journal of biological chemistry 271, 7440-7444 (1996).
    • (1996) The Journal of Biological Chemistry , vol.271 , pp. 7440-7444
    • Zha, H.1    Aime-Sempe, C.2    Sato, T.3    Reed, J.C.4
  • 57
    • 0028834138 scopus 로고
    • Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: Evidence for a novel mechanism of regulating Bcl-2 family protein function
    • Bodrug, S. E. et al. Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function. Cell death and differentiation 2, 173-182 (1995).
    • (1995) Cell Death and Differentiation , vol.2 , pp. 173-182
    • Bodrug, S.E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.